Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 16 of the 28 sources its claims cite were checked for support.

Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial

Open access

Abstract

Background The DiRECT trial assessed remission of type 2 diabetes during a primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention participants were in remission and 36 (24%) had achieved at least 15 kg weight loss. The aim of this 2-year analysis is to assess the durability of the intervention effect. Methods DiRECT is an open-label, cluster-randomised, controlled trial done at primary care practices in the UK. Practices were randomly assigned (1:1) via a computer-generated list to provide an integrated structured weight-management programme (intervention) or best-practice care in accordance with guidelines (control), with stratification for study site (Tyneside or Scotland) and practice list size (>5700 or ≤5700 people). Allocation was concealed from the study statisticians; participants, carers, and study research assistants were aware of allocation. We recruited individuals aged 20-65 years, with less than 6 years' duration of type 2 diabetes, BMI 27-45 kg/m 2, and not receiving insulin between July 25, 2014, and Aug 5, 2016. The intervention consisted of withdrawal of antidiabetes and antihypertensive drugs, total diet replacement (825-853 kcal per day formula diet for 12-20 weeks), stepped food reintroduction (2-8 weeks), and then structured support for weight-loss maintenance. The coprimary outcomes, analysed hierarchically in the intention-to-treat population at 24 months, were weight loss of at least 15 kg, and remission of diabetes, defined as HbA 1c less than 6·5% (48 mmol/mol) after withdrawal of antidiabetes drugs at baseline (remission was determined independently at 12 and 24 months). The trial is registered with the ISRCTN registry, number 03267836, and follow-up is ongoing. Findings The intention-to-treat population consisted of 149 participants per group. At 24 months, 17 (11%) intervention participants and three (2%) control participants had weight loss of at least 15 kg (adjusted odds ratio [aOR] 7·49, 95% CI 2·05 to 27·32; p=0·0023) and 53 (36%) intervention participants and five (3%) control participants had remission of diabetes (aOR 25·82, 8·25 to 80·84; p<0·0001). The adjusted mean difference between the control and intervention groups in change in bodyweight was -5·4 kg (95% CI -6·9 to -4·0; p<0·0001) and in HbA 1c was -4·8 mmol/mol (-8·3 to -1·4 [-0·44% (-0·76 to -0·13)]; p=0·0063), despite only 51 (40%) of 129 patients in the intervention group using anti-diabetes medication compared with 120 (84%) of 143 in the control group. In a post-hoc analysis of the whole study population, of those participants who maintained at least 10 kg weight loss (45 of 272 with data), 29 (64%) achieved remission; 36 (24%) of 149 participants in the intervention group maintained at least 10 kg weight loss. Serious adverse events were similar to those reported at 12 months, but were fewer in the intervention group than in the control group in the second year of the study (nine vs 22). Interpretation The DiRECT programme sustained remissions at 24 months for more than a third of people with type 2 diabetes. Sustained remission was linked to the extent of sustained weight loss. Funding Diabetes UK.

Overview

CoChat Summary

TL;DR

In the 2-year DiRECT trial, a primary care-delivered structured weight-management programme sustained type 2 diabetes remission in 35.6% of intervention participants versus 3.4% of controls. Remission was strongly related to maintained weight loss, occurring in 64% of those maintaining ≥10 kg loss and 70% of those losing ≥15 kg.

Key findings

  • At 24 months, diabetes remission occurred in 53/149 (35.6%) intervention participants versus 5/149 (3.4%) controls (adjusted odds ratio 25.8, 95% CI 8.3–80.8; p<0.0001).
  • Weight loss ≥15 kg occurred in 17/149 (11.4%) intervention participants versus 3/149 (2.0%) controls (adjusted odds ratio 7.49, 95% CI 2.05–27.32; p=0.0023); 24.2% (36/149) of the intervention group maintained ≥10 kg weight loss.
  • Among all participants with weight data, remission at 24 months occurred in 29/45 (64.4%) who maintained ≥10 kg loss and 14/20 (70.0%) who lost ≥15 kg, versus 8/154 (5.2%) who failed to achieve 5 kg loss.
  • Adjusted mean differences at 24 months favoured intervention for weight (−5.43 kg, 95% CI −6.87 to −3.99), HbA1c (−4.82 mmol/mol, 95% CI −8.28 to −1.36), systolic blood pressure (−3.43 mmHg, 95% CI −6.70 to −0.16), and quality-of-life VAS (4.64, 95% CI 0.39–8.89); serious adverse events in the second year were 9 in intervention versus 22 in control.

Methods

  • Open-label, cluster-randomised controlled trial in UK primary care: 49 practices (23 intervention, 26 control), 306 recruited, intention-to-treat population 149 per group; participants were aged 20–65 years, had type 2 diabetes for <6 years, BMI 27–45 kg/m², and were not receiving insulin.
  • Intervention (Counterweight-Plus) comprised total diet replacement (825–853 kcal/day formula diet) for 12–20 weeks, stepped food reintroduction, and structured weight-loss maintenance support; anti-diabetes and antihypertensive drugs were withdrawn at start, with protocols for reintroduction. Controls received best-practice care by guidelines.
  • Co-primary outcomes at 24 months were weight loss ≥15 kg and remission (HbA1c <6.5%/<48 mmol/mol with no anti-diabetes medications); analyses were intention-to-treat using mixed-effects regression with practice as a random effect, and missing primary outcome data were assumed not met.

Limitations

  • The paper states the trial was open-label, so participants and clinicians knew allocation; media coverage after the 12-month results may have attenuated between-group differences, and control-group personal weight loss and increased SGLT2 inhibitor use may have contributed to control-group changes.
  • The paper states findings apply to type 2 diabetes diagnosed within the previous 6 years and may not extrapolate to other racial/ethnic groups such as South Asians; medication withdrawal is not standard guidelines, so some control participants might have sustained HbA1c below the remission cutoff if antidiabetic agents had been withdrawn.
  • The paper states it was not powered for hard clinical outcomes and that exercise and sleep data were not yet analysed; evident from the text, 14.1% (42/298) did not attend the 24-month assessment, and 26 participants with no 24-month data were assumed not to have met either primary outcome.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30068-3

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

7 Valid · 5 Not valid · 7 Not checked · 68 Own results and interpretations

40 more claims

Create a free account to see all 87 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 16
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

22 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 32 references

Cited by

See all 1,017

Metadata

Authors
Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., Welsh, P., Kean, S., Ford, I., McConnachie, A., Messow, C.-M., Sattar, N., & Taylor, R.
Affiliations
  • University of Glasgow (GB)
  • Newcastle University (GB)
Corresponding author
Taylor, Roy
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2019-05
Volume
7
Issue
5
Pages
344-355
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2919203803
Cited by
1,017
References
32
Citations by year
2026: 107 · 2025: 144 · 2024: 179 · 2023: 154 · 2022: 154 · 2021: 131 · 2020: 98 · 2019: 47
FWCI
56.66
Type
journal article
Language
en
Open access
Licence
  • cc-by-sa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Northumbria Research Link (Northumbria University) (acceptedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
Funders
Diabetes UK as a strategic research initiative (13/0004691)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
type 2 diabetes remission, weight management, primary care intervention, total diet replacement, drug withdrawal, weight loss maintenance, HbA1c, weight loss, DIRECT trial, antihypertensive drugs, intention-to-treat analysis
MeSH terms
Adult, Aged, Continuity of Patient Care, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, United Kingdom, Humans, Male, Middle Aged, Primary Health Care, Remission Induction, Time Factors, Cluster Analysis, Young Adult, Weight Reduction Programs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30068-3
The paper
Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., Welsh, P., Kean, S., . . . Taylor, R. (2019). Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30068-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.